Potential future dilution of equity value from stock options
First written in FY2016. 19 of 24 entries say "Worsened", first in FY2017-Q2. Latest entry: FY2025.
atect moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2017: 43 of 78 companies on the "Worse" side.
56 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「③ <Status of Other Stock Acquisition Rights, etc.> Not applicable.」
There were no applicable matters concerning stock acquisition rights, etc. for the year, and no addition to the shares subject to potential future dilution based on the previously outstanding stock acquisition rights was reported. - FY2023MitigatedAnnual report
「Expiry of the 17th Series of Stock Acquisition Rights (expiry date: 15 April 2022; number of shares: 44,500) Expiry of the 18th Series of Stock Acquisition Rights (expiry date: 30 September 2022; number of shares: 73,500)」
The 17th Series covering 44,500 shares and the 18th Series covering 73,500 shares expired, leaving no outstanding stock acquisition rights at the end of the fiscal year. The shares subject to potential future dilution decreased. - FY2023-Q2MitigatedAnnual report
「Expiry of the 17th Series of Stock Acquisition Rights (Expiry date: 15 April 2022 Number of shares: 44,500) Expiry of the 18th Series of Stock Acquisition Rights (Expiry date: 30 September 2022 Number of shares: 73,500)」
A total of 118,000 shares underlying the 17th and 18th Series of Stock Acquisition Rights expired, reducing the shares subject to potential future dilution. - FY2022WorsenedAnnual report
「During the consolidated fiscal year, the exercise of stock options increased the share count by 20,700 shares. In addition, at a meeting of the Board of Directors held on 31 March 2022, a resolution was passed to issue the 18th Series of Stock Acquisition Rights, comprising 735 rights covering 73,500 shares, and the rights were issued on 15 April 2022.」
During the year, 20,700 shares were issued upon the exercise of stock acquisition rights. In addition, after the filing, the 18th Series of Stock Acquisition Rights covering 73,500 shares was issued, adding to the shares subject to potential future dilution. - FY2022-Q2WorsenedAnnual report
「1 July 2021–30 September 2021 4,000 4,436,800 2,440 822,266 2,440 742,266 (Note) Increase resulting from the exercise of stock acquisition rights (stock options).」
During the second quarter, the exercise of stock acquisition rights increased the share count by 4,000 shares, adding to the number of shares that could potentially result in dilution. - FY2022-Q1WorsenedAnnual report
「Change in total shares issued and outstanding 16,700 4,432,800 (Note) 1. Increase resulting from the exercise of stock acquisition rights (stock options).」
During the first quarter, the exercise of stock acquisition rights increased the share count by 16,700 shares, bringing total shares issued and outstanding to 4,432,800. An increase of 2,000 shares in July before the filing date was also reported. - FY2021-Q2WorsenedAnnual report
「Expiry of the 16th Series of Stock Acquisition Rights (Expiry date: 30 April 2020 Number of shares: 25,300) Issue of the 17th Series of Stock Acquisition Rights Stock options granted pursuant to the resolution of the Board of Directors on 15 April 2020 (in the form of stock acquisition rights) (Number of shares: 48,500)」
The 16th Series of Stock Acquisition Rights covering 25,300 shares expired, while the 17th Series covering 48,500 shares was issued, resulting in a net increase in shares subject to potential future dilution. - FY2020WorsenedAnnual report
「1 April 2019–31 March 2020 (Note) Increase resulting from the exercise of stock acquisition rights (stock options). 20,200 4,416,100」
During the year, the exercise of stock acquisition rights increased the share count by 20,200 shares. In addition, after the filing, a resolution was passed to issue the 17th Series of Stock Acquisition Rights covering 48,500 shares, adding to the shares subject to potential future dilution. - FY2020-Q3WorsenedAnnual report
「1 October 2019–31 December 2019 (Note) Increase resulting from the exercise of stock acquisition rights. 3,000 4,402,900」
During the third quarter, the exercise of stock acquisition rights increased the share count by 3,000 shares, bringing total shares issued and outstanding to 4,402,900. - FY2020-Q2WorsenedAnnual report
「1 July 2019–30 September 2019 4,000 4,399,900 2,056 799,757 2,056 719,757 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the second quarter, the exercise of stock acquisition rights increased the share count by 4,000 shares, bringing total shares issued and outstanding to 4,399,900. - FY2020-Q1WorsenedAnnual report
「Between 1 July 2019 and 31 July 2019, the exercise of stock acquisition rights increased total shares issued and outstanding by 2,000 shares and increased both stated capital and capital surplus by ¥964 thousand.」
After the quarter-end, 2,000 shares were additionally issued through the exercise of stock acquisition rights, further increasing the number of shares that could potentially result in dilution. - FY2019WorsenedAnnual report
「Increase from the exercise of stock options 43,300 shares」
During the year, the exercise of stock acquisition rights increased the share count by 43,300 shares, bringing total shares issued and outstanding to 4,395,900. The 16th Series of Stock Acquisition Rights, covering 26,800 shares, also remained unexercised. - FY2019-Q3WorsenedAnnual report
「1 October 2018–31 December 2018 3,000 4,359,600 (Note) 1. Increase resulting from the exercise of stock acquisition rights. 2. Between 1 January 2019 and 31 January 2019, the exercise of stock acquisition rights increased total shares issued and outstanding by 11,000 shares and increased both stated capital and capital surplus by ¥6.710 million.」
During the third quarter, the exercise of stock acquisition rights increased the share count by 3,000 shares, and a further 11,000 shares were issued in January 2019 before the filing date, adding to the number of shares subject to dilution. - FY2019-Q2WorsenedAnnual report
「<16th Series of Stock Acquisition Rights> Date of resolution 8 August 2018 Class, details and number of shares underlying the stock acquisition rights (shares) Common shares 26,800」
The 16th Series of Stock Acquisition Rights was issued, adding 26,800 shares subject to potential future dilution. - FY2019-Q1WorsenedAnnual report
「1 April 2018–30 June 2018 4,000 4,356,600 1,190 777,031 1,190 697,031 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the first quarter, the exercise of stock acquisition rights increased the share count by 4,000 shares, further adding to the number of shares that could potentially result in dilution. - FY2018WorsenedAnnual report
「Fiscal year ended 31 March 2018 (1 April 2017 to 31 March 2018) Summary of changes resulting in an increase in total shares issued and outstanding Increase from the exercise of stock options 37,800 shares」
During the year, the exercise of stock acquisition rights increased the share count by 37,800 shares, bringing total shares issued and outstanding to 4,352,600. - FY2018-Q3WorsenedAnnual report
「Change in total number of issued shares 1,000 4,327,300 (Note) Increase due to the exercise of share acquisition rights.」
During the third quarter, the exercise of stock acquisition rights increased the share count by 1,000 shares, further adding to the number of shares that could potentially dilute future equity value. - FY2018-Q2WorsenedAnnual report
「Change in total number of issued shares 11,500 4,326,300 (Note) Increase due to the exercise of share acquisition rights.」
During the cumulative period of the second quarter, 11,500 shares were added through the exercise of share acquisition rights, bringing the total number of issued shares to 4,326,300. - FY2018-Q1WorsenedAnnual report
「Between 1 July 2017 and 31 July 2017, the total number of issued shares increased by 10,000 through the exercise of share acquisition rights, while capital stock and the capital reserve each increased by ¥4,820 thousand.」
After the end of the quarter, an additional 10,000 shares were issued through the exercise of share acquisition rights, increasing the number of shares that could lead to future dilution of equity value. - FY2017WorsenedAnnual report
「Increase due to the exercise of stock options 73,700 shares」
During the fiscal year, 73,700 shares were added through the exercise of stock options, bringing the total number of issued shares to 4,314,800. Share acquisition rights covering 62,000 shares under Series 15 also remained unexercised. - FY2017-Q3WorsenedAnnual report
「Change in total number of issued shares 26,500 Balance of total number of issued shares 4,267,600 (Note) Increase due to the exercise of share acquisition rights.」
From April through December 2016, 26,500 shares were added through the exercise of share acquisition rights, increasing the number of shares subject to potential future dilution. - FY2017-Q2WorsenedAnnual report
「The share acquisition rights issued during the second quarter accounting period were as follows: Number of shares underlying the share acquisition rights (shares) 76,000」
In addition to an increase of 23,500 shares through the exercise of share acquisition rights during the cumulative period of the quarter, Series 15 share acquisition rights covering 76,000 shares were issued, adding to the shares subject to potential future dilution. - FY2017-Q1MaterialisedAnnual report
「10,000 4,251,100 2,360 740,005 2,360 660,005 (Note) Increase due to the exercise of share acquisition rights.」
During the quarter, 10,000 shares were added through the exercise of share acquisition rights, resulting in an actual event that could lead to future dilution of equity value. - FY2016First statedAnnual report
「The company may grant share acquisition rights as an incentive plan to motivate officers and employees and attract talented personnel. If these share acquisition rights are exercised in the future, the equity value per share may be diluted, potentially affecting the formation of the share price.」
The company describes share acquisition rights as a measure to attract talent and enhance motivation, while identifying future dilution upon exercise as a risk.